4//SEC Filing
RA Capital Healthcare Fund LP 4
Accession 0001231919-25-000547
CIK 0002036042other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 5:43 PM ET
Size
33.9 KB
Accession
0001231919-25-000547
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Sale
Common Stock
2025-11-20$39.89/sh−150$5,984→ 6,898,929 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−801$31,952→ 2,205,034 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−788$31,914→ 660,231 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−96$3,888→ 6,898,833 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−1,210$47,795→ 6,897,623 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−7,609$300,556→ 159,033 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−1,235$49,264→ 661,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−604$24,462→ 166,642 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−9,924$391,998→ 650,307 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−947$37,776→ 167,246 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−512$20,736→ 2,204,522 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−6,440$254,380→ 2,198,082 total(indirect: See footnotes)
RA Capital Healthcare Fund LP
Director10% Owner
Transactions
- Sale
Common Stock
2025-11-20$39.89/sh−1,235$49,264→ 661,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−7,609$300,556→ 159,033 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−947$37,776→ 167,246 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−1,210$47,795→ 6,897,623 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−6,440$254,380→ 2,198,082 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−150$5,984→ 6,898,929 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−801$31,952→ 2,205,034 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−788$31,914→ 660,231 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−96$3,888→ 6,898,833 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−512$20,736→ 2,204,522 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−604$24,462→ 166,642 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−9,924$391,998→ 650,307 total(indirect: See footnotes)
RA Capital Nexus Fund, L.P.
Director
Transactions
- Sale
Common Stock
2025-11-20$39.89/sh−1,235$49,264→ 661,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−150$5,984→ 6,898,929 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−788$31,914→ 660,231 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−604$24,462→ 166,642 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−6,440$254,380→ 2,198,082 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−801$31,952→ 2,205,034 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−947$37,776→ 167,246 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−96$3,888→ 6,898,833 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−512$20,736→ 2,204,522 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−1,210$47,795→ 6,897,623 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−9,924$391,998→ 650,307 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−7,609$300,556→ 159,033 total(indirect: See footnotes)
Shah Rajeev M.
Director10% Owner
Transactions
- Sale
Common Stock
2025-11-21$39.50/sh−6,440$254,380→ 2,198,082 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−1,210$47,795→ 6,897,623 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−512$20,736→ 2,204,522 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−7,609$300,556→ 159,033 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−96$3,888→ 6,898,833 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−604$24,462→ 166,642 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−9,924$391,998→ 650,307 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−150$5,984→ 6,898,929 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−1,235$49,264→ 661,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−801$31,952→ 2,205,034 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−947$37,776→ 167,246 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−788$31,914→ 660,231 total(indirect: See footnotes)
RA Capital Nexus Fund III, L.P.
Director
Transactions
- Sale
Common Stock
2025-11-20$40.50/sh−96$3,888→ 6,898,833 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−512$20,736→ 2,204,522 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−6,440$254,380→ 2,198,082 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−947$37,776→ 167,246 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−1,210$47,795→ 6,897,623 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−7,609$300,556→ 159,033 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−150$5,984→ 6,898,929 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−1,235$49,264→ 661,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−9,924$391,998→ 650,307 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−801$31,952→ 2,205,034 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−788$31,914→ 660,231 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−604$24,462→ 166,642 total(indirect: See footnotes)
Kolchinsky Peter
Director10% Owner
Transactions
- Sale
Common Stock
2025-11-20$40.50/sh−512$20,736→ 2,204,522 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−9,924$391,998→ 650,307 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−6,440$254,380→ 2,198,082 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−1,235$49,264→ 661,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−801$31,952→ 2,205,034 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−947$37,776→ 167,246 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−788$31,914→ 660,231 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−604$24,462→ 166,642 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−1,210$47,795→ 6,897,623 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$39.89/sh−150$5,984→ 6,898,929 total(indirect: See footnotes) - Sale
Common Stock
2025-11-20$40.50/sh−96$3,888→ 6,898,833 total(indirect: See footnotes) - Sale
Common Stock
2025-11-21$39.50/sh−7,609$300,556→ 159,033 total(indirect: See footnotes)
Footnotes (8)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
- [F3]RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F4]Held directly by the Nexus Fund.
- [F5]Held directly by the Nexus Fund III.
- [F6]Held directly by the Account.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $40.51 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Sionna Therapeutics, Inc.
CIK 0002036042
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001315082
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 5:43 PM ET
- Size
- 33.9 KB